Akebia Therapeutics, Inc. [AKBA] is following upward trend in the market concluded with the last trading session. The shares of the Healthcare sector company has a current value of $5.91 after AKBA shares went up by 11.18% during the last trading session. One of the reasons why Healthcare stocks may go bullish is increased momentum in the press.

Akebia Therapeutics, Inc. [NASDAQ:AKBA]: Analyst Rating and Earnings

Its stock price has been found in the range of 2.99 to 10.45. This is compared to its latest closing price of $5.32.

Pay attention for this company’s financial results, of which the next release is scheduled to happen on Tue 12 Nov (21 days ago).

Fundamental Analysis of Akebia Therapeutics, Inc. [AKBA]

Now let’s turn to look at profitability: with a current Operating Margin for Akebia Therapeutics, Inc. [AKBA] sitting at -74.64 and its Gross Margin at +95.83, this company’s Net Margin is now -75.40%. These metrics indicate that this company is not generating as much profit, after accounting for expenses, compared to its market peers.

This company’s Return on Total Capital is -40.26, and its Return on Invested Capital has reached -23.00%. Its Return on Equity is -38.02, and its Return on Assets is -19.49. These metrics suggest that this Akebia Therapeutics, Inc. does a poor job of managing its assets, and likely won’t be able to provide successful business outcomes for its investors in the near term.

Turning to investigate this organization’s capital structure, Akebia Therapeutics, Inc. [AKBA] has generated a Total Debt to Total Equity ratio of 2.36. Similarly, its Total Debt to Total Capital is 2.30, while its Total Debt to Total Assets stands at 1.35.

(adsbygoogle = window.adsbygoogle || []).push({});

What about valuation? This company’s Enterprise Value to EBITDA is -2.89. The Enterprise Value to Sales for this firm is now 1.36, and its Total Debt to Enterprise Value stands at 1.05. Akebia Therapeutics, Inc. [AKBA] has a Price to Book Ratio of 1.02.

Shifting the focus to workforce efficiency, Akebia Therapeutics, Inc. [AKBA] earns $639,206 for each employee under its payroll. Similarly, this company’s Receivables Turnover is 8.17 and its Total Asset Turnover is 0.28. This publicly-traded organization’s liquidity data is also interesting: its Quick Ratio is 1.33 and its Current Ratio is 1.76. This company, considering these metrics, has a healthy ratio between its short-term liquid assets and its short-term liabilities, making it a less risky investment.

Akebia Therapeutics, Inc. [AKBA] has 118.86M shares outstanding, amounting to a total market cap of $632.35M. Its stock price has been found in the range of 2.99 to 10.45. At its current price, it has moved down by -43.40% from its 52-week high, and it has moved up 97.83% from its 52-week low.

This stock’s Beta value is currently 1.71, which indicates that it is 16.58% more volatile that the wider market. This stock’s Relative Strength Index (RSI) is at 68.10. This RSI score is good, suggesting this stock is neither overbought or oversold.

Conclusion: Is Akebia Therapeutics, Inc. [AKBA] a Reliable Buy?

Shares of Akebia Therapeutics, Inc. [AKBA], on the whole, present investors with both positive and negative signals. Wall Street analysts have mixed reviews when it comes to the 12-month price outlook, and this company’s financials show a combination of strengths and weaknesses. Based on the price performance, this investment is somewhat risky while presenting reasonable potential for ROI.